LungLife AI (LLAI) Competitors

Verici Dx (LON:VRCI) and LungLife AI (LON:LLAI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, community ranking, media sentiment and analyst recommendations.

Does the media prefer VRCI or LLAI?

In the previous week, LungLife AI had 1 more articles in the media than Verici Dx. MarketBeat recorded 1 mentions for LungLife AI and 0 mentions for Verici Dx. Verici Dx's average media sentiment score of 0.00 equaled LungLife AI'saverage media sentiment score.

Company	Overall Sentiment
Verici Dx	Neutral
LungLife AI	Neutral

Does the MarketBeat Community favor VRCI or LLAI?

Verici Dx and LungLife AI both received 0 outperform votes by MarketBeat users.

Company	Underperform	Outperform
Verici Dx	N/A	N/A
LungLife AI	N/A	N/A

Which has preferable earnings and valuation, VRCI or LLAI?

LungLife AI has lower revenue, but higher earnings than Verici Dx. Verici Dx is trading at a lower price-to-earnings ratio than LungLife AI, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verici Dx	£4.33M	2.38	-£4.81M	-£0.02	-212.50
LungLife AI	£98.57K	34.22	-£4.47M	-£0.13	-84.62

Is VRCI or LLAI more profitable?

LungLife AI has a net margin of 0.00% compared to Verici Dx's net margin of -110.99%. LungLife AI's return on equity of -48.59% beat Verici Dx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verici Dx	-110.99%	-58.12%	-26.14%
LungLife AI	N/A	-48.59%	-27.28%

Which has more volatility and risk, VRCI or LLAI?

Verici Dx has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500. Comparatively, LungLife AI has a beta of -0.3, suggesting that its share price is 130% less volatile than the S&P 500.

Do institutionals & insiders hold more shares of VRCI or LLAI?

51.9% of Verici Dx shares are held by institutional investors. Comparatively, 42.5% of LungLife AI shares are held by institutional investors. 17.1% of Verici Dx shares are held by insiders. Comparatively, 48.4% of LungLife AI shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

LungLife AI beats Verici Dx on 7 of the 12 factors compared between the two stocks.